Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Danielle Pasqualone | M | - | 5 years | |
Louis Lavigne | M | 75 | 6 years | |
Richard Scheller | M | 70 | 6 years | |
David Wehner | M | 54 | 6 years | |
Marc Grasso | M | 51 | 2 years | |
Saraswati Kenkare-Mitra | M | 56 | 3 years | |
Kristine Yaffe | M | 61 | 5 years | |
Paula Hammond | M | 60 | 4 years | |
Elizabeth Garofalo | M | 66 | 3 years | |
Kristina Cutter | F | - | 5 years | |
Clare Hunt | F | - | 7 years | |
Gary Romano | M | 63 | 2 years | |
Charles Wolfus | M | - | 5 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Hong Zhao | M | 60 | - | |
Shehnaaz Suliman | M | 52 | 3 years | |
Ira D. Lawrence | M | 71 | 8 years | |
Carey Chern | M | 57 | 2 years | |
Calvin Yu | M | 48 | - | |
Wai Shun Cheung | M | 55 | - | |
Charles Homcy | M | 75 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 14 years |
Charles Meng | M | - | 2 years | |
R. Lee Douglas | M | 72 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 10 years |
Michelle Corral | F | - | 1 years | |
James Topper | M | 62 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 4 years |
Peter Barrett | M | 71 | 2 years | |
Carl Gordon | M | 59 | 6 years | |
Nancy T. Chang | M | 74 | 4 years | |
Simon Li | M | 74 | 4 years | |
Raymond Anthony Low | M | 67 | 5 years | |
Gregg Lapointe | M | 65 | 7 years | |
Gary Titus | M | 64 | 5 years | |
Min Yin | F | 53 | - | |
Trevor Jones | M | 82 | 3 years | |
Linda Rubinstein | F | 58 | 1 years | |
Sam Jackson | M | - | - | |
Mark Gavin Lotter | M | 62 | 1 years | |
John J. Schembri | M | 62 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 4 years |
Tony L. Alarcon | M | - |
San Jose State University
| 2 years |
Jason Allen | M | - |
San Jose State University
| 4 years |
Mark Oki | M | 55 |
San Jose State University
| 4 years |
Jennifer A. Troia | F | - |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 5 years |
Joanne Quan | M | 60 |
Bayhill Therapeutics, Inc.
Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | 3 years |
Jennifer Graham | F | - |
San Jose State University
| 2 years |
Kwang S. Lee | M | - |
Bayhill Therapeutics, Inc.
Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | 4 years |
Tony Huang | M | - |
San Jose State University
| 4 years |
N. Shekhar | M | 63 |
San Jose State University
| 2 years |
Scott F. Schimberg | M | - |
San Jose State University
| 4 years |
Patrick A. Broderick | M | 66 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 3 years |
Stephanie Wong | F | 50 | 4 years | |
Bum-Soo Kim | M | 64 |
San Jose State University
| 1 years |
Asa Abeliovich | M | 60 | 4 years | |
Seon-Joong Kim | M | - |
San Jose State University
| 1 years |
Hong He | M | 55 | 4 years | |
Monica van Berkel | F | 55 |
San Jose State University
| 1 years |
Stephanie Yonker | M | - | - | |
Sabah Oney | M | 41 | 5 years | |
Carla Fiankan | F | - |
San Jose State University
| 2 years |
Scott Brown | M | 43 | 1 years | |
Tsz Hin Ngai | M | 35 | - | |
Brian Sander | M | - | - | |
Sunny Lee Ryan | F | 54 |
Rinat Neuroscience Corp.
Rinat Neuroscience Corp. BiotechnologyHealth Technology Rinat Neuroscience Corp. manufactures and markets drugs for treating neurological diseases. The company was founded by Arnon Rosenthal and Patrick G. Lynn on November 21, 2000 and is headquartered in South San Francisco, CA. | 1 years |
Nicholas Maestas | M | 44 | 2 years | |
Frank Carbajal | M | - |
San Jose State University
| 2 years |
Scott Webber | M | - |
San Jose State University
| 4 years |
Ron Kundich | M | 53 |
San Jose State University
| 2 years |
Alfonso de la Nuez Magarzo | M | 51 |
San Jose State University
| 4 years |
Frank Valone | M | 74 |
Bayhill Therapeutics, Inc.
Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | 5 years |
James Moniz | M | 66 |
San Jose State University
| 1 years |
Richard P. Powers | M | 80 |
Bayhill Therapeutics, Inc.
Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | 5 years |
Todd J. Lorenz | M | 70 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 7 years |
Jan K. Hughes | M | - |
Molecular Devices LLC
Molecular Devices LLC Medical SpecialtiesHealth Technology Molecular Devices LLC engages in the provision of bioanalytical solutions for protein and cell biology in life science research, pharmaceutical, and bio-therapeutic development. Its product portfolio includes platforms for screening, genomic and cellular analysis, colony selection, and microplate detection. The company was founded by Harden M. McConnell in July, 1983 and is headquartered in San Jose, CA. | - |
Ronald Eastman | M | 71 |
Rinat Neuroscience Corp.
Rinat Neuroscience Corp. BiotechnologyHealth Technology Rinat Neuroscience Corp. manufactures and markets drugs for treating neurological diseases. The company was founded by Arnon Rosenthal and Patrick G. Lynn on November 21, 2000 and is headquartered in South San Francisco, CA. | 4 years |
Roop Kalyan Lakkaraju | M | 53 |
San Jose State University
| 4 years |
Fred Kurland | M | 74 |
Bayhill Therapeutics, Inc.
Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | 1 years |
Michael M. Kitt | M | 73 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 9 years |
Mark D. Perrin | M | 67 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 6 years |
Wing-Kei Tso | F | 63 | - | |
Jie Jackie Guan | M | - | - | |
Roberto Camerini | M | 61 | 2 years | |
Sarvajit Chakravarty | M | 58 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 14 years |
Robert Gifford | M | 66 |
San Jose State University
| 4 years |
John P. Longenecker | M | 76 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 10 years |
David Liu | M | 73 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 10 years |
Lan Xie | F | 51 | - | |
Lee Michael Byungnam | M | - |
San Jose State University
| 3 years |
William Lis | M | 59 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 3 years |
Daniel D. Gretler | M | - |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 7 years |
Andrew J. Williams | M | - |
San Jose State University
| 4 years |
David Oh | M | - | - | |
Patricia Ann Walicke | M | 71 |
Rinat Neuroscience Corp.
Rinat Neuroscience Corp. BiotechnologyHealth Technology Rinat Neuroscience Corp. manufactures and markets drugs for treating neurological diseases. The company was founded by Arnon Rosenthal and Patrick G. Lynn on November 21, 2000 and is headquartered in South San Francisco, CA. | 2 years |
Paul B. Westberg | M | 56 |
Bayhill Therapeutics, Inc.
Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | 4 years |
Kevin Choy | M | - |
San Jose State University
| 4 years |
Arlene Morris | F | 72 |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | 3 years |
Israel Rios | M | 77 | 7 years | |
Rosina Maar Pavia | M | 61 |
Bayhill Therapeutics, Inc.
Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | 6 years |
Thomas Hancock | M | 60 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 5 years |
Robert J. Terifay | M | 64 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 6 years |
Robert Zuk | M | - |
Molecular Devices LLC
Molecular Devices LLC Medical SpecialtiesHealth Technology Molecular Devices LLC engages in the provision of bioanalytical solutions for protein and cell biology in life science research, pharmaceutical, and bio-therapeutic development. Its product portfolio includes platforms for screening, genomic and cellular analysis, colony selection, and microplate detection. The company was founded by Harden M. McConnell in July, 1983 and is headquartered in San Jose, CA. | 5 years |
Vartan E. Ghazarossian | M | - |
Molecular Devices LLC
Molecular Devices LLC Medical SpecialtiesHealth Technology Molecular Devices LLC engages in the provision of bioanalytical solutions for protein and cell biology in life science research, pharmaceutical, and bio-therapeutic development. Its product portfolio includes platforms for screening, genomic and cellular analysis, colony selection, and microplate detection. The company was founded by Harden M. McConnell in July, 1983 and is headquartered in San Jose, CA. | 3 years |
Rich Bodo | M | - |
San Jose State University
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Robert King
- Personal Network